The pharmaceutical industry occupies an unusually prominent position in discussions of IP policy and has been at the center of both domestic and international disputes over the interplay between IPRs, R&D incentives, price, and patient access. Despite the fervour of debate surrounding some key issues, there is comparatively little actual data to guide policy-making. This article reviews the empirical literature on intellectual property and pharmaceuticals, analyses methodological issues and important data sources, and outlines some of the most important research questions and knowledge gaps.
Post Views: 640